Therapeutic effects of desmopressin in primary monosymptomatic noctural enuresis treatment depending on Patients' Age

被引:2
作者
Radojicic, Zoran [1 ]
Milivojevic, Sasa [1 ]
Lazovic, Jelena Milin [2 ]
Toplicic, Djordje [1 ]
Milic, Natasa [2 ,3 ]
机构
[1] Univ Childrens Hosp, Belgrade, Serbia
[2] Univ Belgrade, Fac Med, Inst Med Stat & Informat, Belgrade, Serbia
[3] Mayo Clin, Dept Internal Med, Rochester, MN USA
关键词
Desmopressin; Primary monosymptomatic nocturnal enuresis; Children; FUNCTIONAL BLADDER CAPACITY; CHILDREN; STANDARDIZATION; MANAGEMENT;
D O I
10.1016/j.jpurol.2020.08.003
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Purpose To test the therapeutic effects of Desmopressin (dDAVP) in primary monosymptomatic nocturnal enuresis (PMNE) treatment depending on patients' age. Material and methods The prospective research was carried out in the 2014-2018 period, during which 89 patients were observed who were treated with dDAVP due to the previously diagnosed PMNE. The patients were divided into two age groups. The first group (Group 1) consisted of 43 patients age 5 to 6, with the average age of 5.6 +/- 0.5, out of whom 35 (81.4%) were boys, and 8 (18.6%) girls. The second group (Group 2) consisted of 46 patients age over 7 to 12, with the average age of 9.7 +/- 1.6, out of whom 30 (65.2%) were boys, and 16 (34.8%) were girls. There was no statistically relevant difference according to sex (p = 0.086). After the 3-month treatment, all the patients in both groups were tested for the effects of dDAVP in PMNE treatment. Results The average enuresis frequency in the first group (Group 1) before therapy was 26.0 +/- 6.2 per month, whereas the average enuresis frequency after therapy was 11.0 +/- 8.0 per month (p = 0.040). The average enuresis frequency in the second group (Group 2) before therapy was 23.1 +/- 6.2 per month, whereas the average enuresis frequency after therapy was 3.8 +/- 3.6 per month (p = 0.036). ANOVA data analysis of repeated measurements has indicated that there is a statistically relevant interaction between the groups (p = 0.006), i.e. enuresis frequency decreases considerably more in the second group (Group 2). Conclusion PMNE with dDAVP is noticeably more effective with patients over 7 years of age. [GRAPHICS] .
引用
收藏
页码:646.e1 / 646.e7
页数:7
相关论文
共 50 条
  • [31] Reduced anti-diuretic response to desmopressin during wet nights in patients with monosymptomatic nocturnal enuresis
    Tauris, Lene Hjelle
    Andersen, Rene Frydensbjerg
    Kamperis, Konstantinos
    Hagstroem, Soren
    Rittig, Soren
    JOURNAL OF PEDIATRIC UROLOGY, 2012, 8 (03) : 285 - 290
  • [32] The adverse influence of spina bifida occulta on the medical treatment outcome of primary monosymptomatic nocturnal enuresis
    Cakiroglu, Basri
    Tas, Tuncay
    Eyyupoglu, Seyit Erkan
    Hazar, Aydin Ismet
    Balci, Mustafa Bahadir Can
    Nas, Yunus
    Yilmazer, Fazli
    Aksoy, Suleyman Hilmi
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2014, 86 (04) : 270 - 273
  • [33] Combination therapy (desmopressin plus oxybutynin) improves the response rate compared with desmopressin alone in patients with monosymptomatic nocturnal enuresis and nocturnal polyuria and absence of constipation predict the response to this treatment
    Daniela Capalbo
    Stefano Guarino
    Anna Di Sessa
    Claudia Esposito
    Carolina Grella
    Alfonso Papparella
    Emanuele Miraglia del Giudice
    Pierluigi Marzuillo
    European Journal of Pediatrics, 2023, 182 : 1587 - 1592
  • [34] Does desmopressin withdrawal strategy affect relapse rates in monosymptomatic enuresis treatment?
    Yasar Issi
    Unal Biçakci
    European Journal of Pediatrics, 2021, 180 : 1453 - 1457
  • [35] Is There Still a Role for Desmopressin in Children with Primary Monosymptomatic Nocturnal Enuresis? A Focus on Safety Issues
    Van de Walle, Johan
    Van Herzeele, Charlotte
    Raes, Ann
    DRUG SAFETY, 2010, 33 (04) : 261 - 271
  • [36] Is There Still a Role for Desmopressin in Children with Primary Monosymptomatic Nocturnal Enuresis?A Focus on Safety Issues
    Johan Van de Walle
    Charlotte Van Herzeele
    Ann Raes
    Drug Safety, 2010, 33 : 261 - 271
  • [37] Comparative Analysis of Solifenacin Plus Desmopressin Versus Desmopressin Alone in the Treatment of Primary Mono Symptomatic Nocturnal Enuresis
    Ahmad, Tariq
    Minallah, Nasrum
    JOURNAL OF PEDIATRIC SURGERY, 2023, 58 (10) : 2034 - 2037
  • [38] Fluoxetine, a selective serotonin reuptake inhibitor, versus desmopressin in primary monosymptomatic nocturnal enuresis: A randomised controlled trial
    Hashem, Abdelwahab
    Torad, Hesham
    Soleiman, Ahmed Mohamed
    El-Helaly, Hesham Abdel-Azim
    ARAB JOURNAL OF UROLOGY, 2025,
  • [39] Evaluation of Urinary Aquaporin 2 and Plasma Copeptin as Biomarkers of Effectiveness of Desmopressin Acetate for the Treatment of Monosymptomatic Nocturnal Enuresis
    Hara, Taichi
    Ohtomo, Yoshiyuki
    Endo, Amane
    Niijima, Shinichi
    Yasui, Masato
    Shimizu, Toshiaki
    JOURNAL OF UROLOGY, 2017, 198 (04) : 921 - 927
  • [40] Hyponatraemic convulsion secondary to desmopressin treatment for primary enuresis
    Apakama, DC
    Bleetman, A
    JOURNAL OF ACCIDENT & EMERGENCY MEDICINE, 1999, 16 (03): : 229 - 230